Ubs Group Ag Cv Rx, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Cv Rx, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 25,159 shares of CVRX stock, worth $324,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,159

Previous 19,388 29.77%

Holding current value

$324,551

Previous $232,000 4.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.15 - $12.37 $41,262 - $71,387	5,771 Added 29.77%	25,159 $221,000
Q2 2024 Aug 13, 2024	BUY	$6.49 - $19.2 $51,225 - $151,545	7,893 Added 68.66%	19,388 $232,000
Q1 2024 May 13, 2024	SELL	$17.99 - $30.49 $16,424 - $27,837	-913 Reduced 7.36%	11,495 $209,000
Q4 2023 Feb 09, 2024	BUY	$11.67 - $33.01 $71,793 - $203,077	6,152 Added 98.34%	12,408 $390,000
Q3 2023 Nov 09, 2023	SELL	$13.56 - $18.47 $12,339 - $16,807	-910 Reduced 12.7%	6,256 $94,000
Q2 2023 Aug 11, 2023	BUY	$8.57 - $15.44 $56,270 - $101,379	6,566 Added 1094.33%	7,166 $110,000
Q3 2022 Nov 10, 2022	SELL	$6.12 - $9.5 $32,552 - $50,530	-5,319 Reduced 89.86%	600 $6,000
Q2 2022 Aug 10, 2022	BUY	$4.7 - $7.22 $587 - $902	125 Added 2.16%	5,919 $36,000
Q1 2022 May 16, 2022	SELL	$5.62 - $12.37 $24,525 - $53,982	-4,364 Reduced 42.96%	5,794 $35,000
Q4 2021 Feb 14, 2022	BUY	$10.65 - $18.61 $16,592 - $28,994	1,558 Added 18.12%	10,158 $125,000
Q3 2021 Nov 15, 2021	BUY	$14.65 - $26.07 $113,405 - $201,807	7,741 Added 901.16%	8,600 $142,000
Q2 2021 Aug 13, 2021	BUY	$28.0 - $28.0 $24,052 - $24,052	859 New	859 $24,000

Others Institutions Holding CVRX

# of Institutions

Shares Held

14.4M

Call Options Held

56.3K

Put Options Held

41.8K

View Full List

About CVRx, Inc.

Ticker CVRX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,576,200
Market Cap $265M
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...

More about CVRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account